Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
Join
FREE
Edition
European
US
Dermatology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Tralokinumab – Updates in Atopic Dermatitis
8
Mins
January 2026
A summary of new data on tralokinumab in atopic dermatitis, presented at conferences/symposia held between September and October 2024.
Read more
10
Mins
20 Oct 2021
Efficacy and Safety of Monoclonal Antibody Therapies in Patients with Moderate-to-Severe Plaque Psoriasis
In the late-breaking research sessions, Reich presented BE RADIANT, the first Phase III trial to compare inhibition of IL-17A and IL-17F…
6
Mins
15 Oct 2021
Where Do We Begin? The Key Role of the IL-23 Pathway in Psoriasis and Psoriatic Arthritis
This Janssen-sponsored live satellite symposium, entitled ‘Where do we begin? The key role of the IL-23 pathway in psoriasis and psoriatic…
9
Mins
17 Jun 2021
Pioneering Best Practices in Atopic Dermatitis: Results from the Quality of Care Initiative
Pioneering global best practices in atopic dermatitis (AD) and implementing them in the clinic are important steps towards optimising patient care…
10
Mins
29 Mar 2021
Advancing Breakthrough Innovative Treatment in Paediatric Dermatitis and Various Skin Disorders
Eczematous dermatitis (or eczema) includes AD, CD, and DD. This inflammatory skin reaction presents as erythema, vesicles, desquamation…
15
Mins
23 Mar 2021
The Treatment Landscape of Atopic Dermatitis: Interviews with Three Consultant Dermatologists
Atopic dermatitis (AD), sometimes referred to as ‘atopic eczema’, is a common, chronic, pruritic, Type II inflammatory skin disease which is associated…
11
Mins
25 Feb 2021
Clinical Considerations Based On 5-Year Efficacy and Safety Data for the IL-23p19 Inhibitor Tildrakizumab
The indicative scaly, erythematous plaques of plaque psoriasis arise because of abnormal interactions between immune system cells and epidermal…
9
Mins
18 Feb 2021
Biological and Clinical Impacts of Ultraviolet-A on the Skin: New Insights
Terrestrial solar UVR consists of UVA (320–400 nm) and UVB (280–320 nm; typically around 295–320nm because of attenuation by the ozone…
11
Mins
10 Feb 2021
Long-term Efficacy and Safety of Tildrakizumab: 5-year Results from the reSURFACE 1 and 2 Phase III Trials in Patients with Moderate-to-severe Plaque Psoriasis
Psoriasis, a chronic systemic inflammatory disease with skin manifestations, can be an impediment to daily life. Accordingly…
Loading posts...
« Previous
1
2
3
4
5
6
…
12
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View